Is the National Institute for Health and Care Excellence (NICE) in England more "innovation-friendly" than the Federal Joint Committee (G-BA) in Germany?

CONCLUSIONS: NICE evaluates new drugs more favorably than G-BA. However, our analysis suggests differences by therapeutic area. Results indicate that different methods are associated with systematic differences in HTA outcomes. PMID: 30556745 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research